APA

Pavone-Macaluso M., Schröder F. H., de Voogt H. J., Viggiano G., Barasolo E., Lardennois B., de Pauw M., Sylvester R., Smith P. H. & Suciu S. (19891023). EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. : Progress in clinical and biological research.

Chicago

Pavone-Macaluso M, Schröder F H, de Voogt H J, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith P H and Suciu S. 19891023. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. : Progress in clinical and biological research.

Harvard

Pavone-Macaluso M., Schröder F. H., de Voogt H. J., Viggiano G., Barasolo E., Lardennois B., de Pauw M., Sylvester R., Smith P. H. and Suciu S. (19891023). EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. : Progress in clinical and biological research.

MLA

Pavone-Macaluso M, Schröder F H, de Voogt H J, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith P H and Suciu S. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. : Progress in clinical and biological research. 19891023.